MaxCyte, Inc. (NASDAQ:MXCT) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

Doug Doerfler – President and Chief Executive Officer

Amanda Murphy – Chief Financial Officer

Sean Menarguez – Investor Relations

Conference Call Participants

Stephanie Iannetta – Cowen and Company

Matthew Larew – William Blair

Mark Belford – Stephens Inc.

Vidyun Bais – BTIG

Operator

Good day and thanks for standing by.

Operator

Good day and thank you for standing by. Welcome tot he MaxCyte First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer-session [Operator Instructions] I will now like to hand the conference over to speaker today, Sean Menarguez, Director of Investor Relations. Please, Go ahead.

Sean Menarguez

Good afternoon, everyone. My name is Sean Menarguez and I'm the Director of Investor Relations here at MaxCyte. Thank you all for participating in today's conference call. On the call from MaxCyte, we have Doug Doerfler, President and Chief Executive Officer Officer, and Ron Holtz, Interim Chief Financial Officer. Earlier today, MaxCyte released financial results for the first quarter ended March 31st, 2022. A copy of the press release is available on the company's website. Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws.

Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors which are discussed in detail in our SEC filings. The company undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Doug.

Doug Doerfler

Thank you, Sean. And good afternoon, everyone. And thank you for joining MaxCyte First Quarter earning call. I'll begin with the discussion of our business and operational headline during the quarter and follow that, a detailed financial review from [Indiscernible]. We will then open the call for questions. We are very pleased with the start to 2022. As our team continue to deliver on all financial and strategic objectives in our plan. MaxCyte ExPERT platform continues to be the premier cell-engineering technology enabling the development of our growing set of advanced cell-base therapeutics. With our additional resources at hand, we continue to invest in our people and capabilities as measured but healthy rate as we seek to ensure the success of our partners.